ARGOS THERAPEUTICS INC (OTCMKTS:ARGS)’s Stock Is Sell After More Market Selling

September 16, 2018 - By Matthew Richard

Argos Therapeutics, Inc. (OTCMKTS:ARGS) Logo

The stock of ARGOS THERAPEUTICS INC (OTCMKTS:ARGS) registered an increase of 380% in short interest. ARGS’s total short interest was 9,600 shares in September as published by FINRA. Its up 380% from 2,000 shares, reported previously. With 81,400 shares average volume, it will take short sellers 0 days to cover their ARGS’s short positions.

The stock decreased 0.38% or $0.00041 during the last trading session, reaching $0.10779. About 21,029 shares traded. Argos Therapeutics, Inc. (OTCMKTS:ARGS) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $1.14 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.